摘要
目的:评价咪唑斯汀联合酮替芬递减疗法治疗慢性荨麻疹的疗效。方法:将入选的209例受试者随机分为2组,试验组106例采用咪唑斯汀联合酮替芬递减疗法;对照组103例,采用咪唑斯汀递减方法。疗程均为10周。结果:试验组和对照组的有效率及停药4周后复发率分别为76.1%、10.4%和43.5%、22.8%。两组有效率及复发率比较,差异均有统计学意义(P<0.05)。两组药物的不良反应主要为口干和嗜睡。结论:相对于咪唑斯汀递减疗法,咪唑斯汀联合酮替芬递减疗法治疗慢性荨麻疹疗效佳、安全性高、复发率低,不良反应与单用咪唑斯汀相似。
Objective： To evaluate the efficacy of Mizolastine and Ketotifen with gradual dose reduction for treating chronic urticaria. Methods： 209 patients were randomly divided into two groups： experimental group （106 cases） and control group （103 cases）. The former were given Mizolastine and Ketotifen with gradual dose reduction for 10 weeks while the latter were given Mizolastine alone with gradual dose reduction for 10 weeks. Results： The total effective rates for experimental group and control group were 76.1% and 43.5%, respectively （P〈 0.05）. 4 weeks after post-treatment, the recurrence rates for experimental group and control group were 10.4% and 22.8% respectively （P〈 0.05）. Adverse effects included dry mouth and drowsiness. Conclusion： In comparison with Mizolastine alone, combination of Mizolastine and Ketotifen with gradual dose reduction shows higher efficacy, better safety and lower recurrence rate. The adverse effects are similar between two groups.
出处
《临床皮肤科杂志》
CAS
CSCD
北大核心
2013年第11期697-699,共3页
Journal of Clinical Dermatology
关键词
慢性荨麻疹
递减疗法
咪唑斯汀
酮替芬
chronic urticaria
decremental therapy
mizolastine
ketotifen
